BACE1 and diabetes mellitus: Treatment with the BACE1 inhibitor LY2886721 also improves diabetic phenotypes in neuronal human BACE1 knock-in (PLB4) mice, a model for high comorbidity of DM and AD (Dekeryte et al., 2021).